Supplemental Table 1 from A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1. IMC-A12 trough serum concentrations during cycle 1 and cycle 2
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361919437